Compounded Semaglutide
a once-weekly GLP-1 receptor agonist
0.25 MG → 2.4 MG · 4-week vial supply
Then $165/mo until canceled. Cancel anytime by emailing support@healthrx.com. Medication if prescribed, clinician review and shipping included. Separate prepaid plans are also available.
We email you before any change to your renewal price or billing period. Subscription cancellation and refund terms.
- Free overnight shipping · all 50 states
- No insurance required
- MD-reviewed intake · US-licensed pharmacy
- If a licensed provider decides the treatment is not right for you, you are not charged for the medication.
Semaglutide acts on GLP-1 receptors involved in glucose regulation and appetite. A clinician reviews your health history, medications, and treatment goals before deciding whether this compounded preparation is appropriate.
How it works in the body
Semaglutide is a long-acting synthetic analog of human GLP-1, the gut hormone released after a meal. By binding to the GLP-1 receptor, it slows gastric emptying, amplifies the body's satiety signaling in the hypothalamus, and improves glucose-dependent insulin secretion. The effects of a particular preparation depend on its formulation and the individual clinical situation.
The dose ladder.
| Week | Dose | Note |
|---|---|---|
| Weeks 01–04 | 0.25 mg / week | Initiation. Lowest dose, designed to acclimate the gut. |
| Weeks 05–08 | 0.5 mg / week | First dose escalation. Most appetite changes start here. |
| Weeks 09–12 | 1.0 mg / week | Provider check-in. Re-evaluate tolerance and response. |
| Weeks 13–16 | 1.7 mg / week | Therapeutic dose for many patients. |
| Weeks 17+ | 2.4 mg / week | Maintenance dose, only if tolerated and clinically appropriate. |
Questions for your care plan.
Side effects, honestly.
Common
- · Nausea (most common during titration)
- · Diarrhea or constipation
- · Decreased appetite (the therapeutic effect)
- · Mild headache, fatigue
- · Burping, indigestion
Serious
- · Pancreatitis (rare)
- · Gallbladder disease
- · Hypoglycemia (especially with other diabetes medications)
- · Possible thyroid C-cell tumors (animal studies in rats; relevance to humans unknown)
Who it's for. Who it isn't.
Suitable for
- · Adults with BMI ≥ 30, or BMI ≥ 27 with a weight-related condition
- · Patients new to GLP-1 therapy
- · Patients whose clinician determines that the proposed preparation is appropriate
Not suitable for
- · Personal or family history of medullary thyroid carcinoma
- · Multiple Endocrine Neoplasia syndrome type 2 (MEN-2)
- · History of severe pancreatitis
- · Pregnant or breastfeeding
- · Severe gastrointestinal disease
Questions, answered.
How much does compounded semaglutide cost at HealthRX.com?
Monthly Subscribe & Save is $149 for the first month, then $165/mo until canceled. Medication if prescribed, clinician review and shipping included. Separate prepaid plans are also available. No insurance required.
Is compounded semaglutide the same as Wegovy or Ozempic?
Semaglutide is the active molecule in branded Wegovy and Ozempic. The HealthRX.com preparation is compounded by a licensed 503A pharmacy on a valid, patient-specific prescription. It is not the branded product.
How much weight can I expect to lose on semaglutide?
STEP 1 studied a specific once-weekly injectable semaglutide product, not the compounded preparation offered here. Its average results cannot predict your response. Your clinician reviews treatment goals, progress, and tolerability with you.
How is semaglutide dosed?
Semaglutide is a once-weekly injection titrated from 0.25 mg up to a maintenance dose (up to 2.4 mg) over several months, escalated only as tolerated and clinically appropriate under provider supervision.
Who should not take semaglutide?
Semaglutide is not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN-2, a history of severe pancreatitis, or during pregnancy or breastfeeding. A licensed clinician reviews your history before prescribing.
The published evidence.
- 01Wilding et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). NEJM 2021.
- 02Davies et al. STEP-2: semaglutide in adults with type 2 diabetes. Lancet 2021.
- 03Lincoff et al. SELECT trial: semaglutide and cardiovascular outcomes in obesity. NEJM 2023.
- 04FDA Prescribing Information: Wegovy and Ozempic (semaglutide).
CERT 50087439 · 503A PHARMACY
LICENSED CLINICIAN REVIEW
Researching your options? Explore the full GLP-1 medicine library or compare compounded semaglutide and compounded tirzepatide.